TrialLupus2025

Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trial.

Richard Furie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.